Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 126

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 126
---
43 million for the three months ended September 30, 2025 and 2024, respectively, an increase in our operating results of $52 million. This increase primarily reflects the increase in contribution and favorable change in other (income) expense, partially offset by the increase in SG&A and R&D, each as previously discussed.Segment ProfitSegment profit is based on operating (loss) income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. Segment profit is a measure of operating performance of our reportable segments and may not be comparable to similar measures reported by other companies. Segment profit is a performance metric utilized by the Company’s Chief Executive Officer, who is the Company’s Chief Operating Decision Maker, to allocate resources to and assess performance of the Company’s segments. See Note 17, “SEGMENT INFORMATION” to our unaudited interim Condensed Consolidated Financial Statements for a reconciliation of segment profit to Income before provision for income taxes.

44

The following table presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended September 30, 2025 and 2024.20252024Change(in millions)AmountPct.AmountPct.AmountPct.Segment Profits / Segment Profit MarginsVision Care$217 29 %$201 29 %$16 8 %Pharmaceuticals76 23 %69 23 %7 10 %Surgical8 4 %13 6 %(5)(38)%Vision Care Segment ProfitThe Vision Care segment profit was $217 million and $201 million for the three months ended September 30, 2025 and 2024, respectively, an increase of $16 million. The increase was primarily driven by the increase in revenue, partially offset by higher selling expense.Pharmaceuticals Segment ProfitThe Pharmaceuticals segment profit was $76 million and $69 million for the three months ended September 30, 2025 and 2024, respectively, an increase of $7 million. The increase was primarily driven by increased sales of MIEBO®, partially offset by: (i) declines in the U.S. generics business, (ii) higher royalties and manufacturing variances and (iii) higher R&D expense.Surgical Segment ProfitThe Surgical segment profit was $8 million and $